Payments by company
Table 2 presents the distribution of payments and amounts by the top 10 companies. Of the 84 companies contributing payments, the foremost 10 and 20 companies, by total payment magnitude, were responsible for 64.6% ($28.0 million) and 83.8% ($36.4 million) of all payments within the 2016 to 2020 timeframe. AstraZeneca made the largest total payments amounting to 14.0% of all payments ($6.1 million) in monetary value, followed by Boehringer Ingelheim Japan ($4.1 million, 9.4%), Novartis Pharma ($3.2 million, 7.4%), Kyorin Pharmaceutical ($2.6 million, 6.0%), and Mitsubishi Tanabe Pharma ($2.4 million, 5.6%). Regarding the number of allergists receiving payments, Kyorin Pharmaceutical was at the forefront, providing payments to 994 allergists (25.2% of all allergists), with AstraZeneca following closely at 884 allergists (22.4%), and Novartis Pharma at 799 allergists (20.3%), over the span of five years.